---
title: List of Clinical Trials
permalink: /singapore-myeloma-tumour-group/clinicaltrials/
variant: tiptap
description: ""
---
<table><tbody><tr><td rowspan="1" colspan="1"><p><strong>Protocol Title and Number</strong>&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>Patient Selection</strong>&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>Main Inclusion/Exclusion Criteria</strong>&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>Sponsor</strong>&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>PI</strong>&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>Contact</strong>&nbsp;</p></td></tr><tr><td rowspan="1" colspan="1"><p><strong>DRUG STUDIES</strong>&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong> </strong>&nbsp;</p></td><td rowspan="1" colspan="1"><p> &nbsp;</p></td><td rowspan="1" colspan="1"><p> &nbsp;</p></td><td rowspan="1" colspan="1"><p><strong> </strong>&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong> </strong>&nbsp;</p></td></tr><tr><td rowspan="1" colspan="1"><p>209626/01 - A Phase I Study to Evaluate the Pharmacokinetics and Safety of<strong> GSK2857916</strong> Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)&nbsp;</p></td><td rowspan="1" colspan="1"><p>Relapse MM with impaired renal function. GFR &lt;15ml/min&nbsp;</p></td><td rowspan="1" colspan="1"><p>Has failed at least 2 prior lines of anti-myeloma treatments, including an immunomodulatory drug (e.g., lenalidomide or pomalidomide) and a proteasome inhibitor (e.g., ortezomib, ixazomib or carfilzomib).&nbsp;</p></td><td rowspan="1" colspan="1"><p>GSK&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>NCIS Chng WJ&nbsp;</strong>&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>NCIS: </strong>&nbsp;<br><strong>SGH:</strong>&nbsp;<br><strong>TTSH:&nbsp;</strong>&nbsp;</p></td></tr><tr><td rowspan="1" colspan="1"><p>CA057-008 - A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing<strong> CC-92480 </strong>(<strong>BMS-986348), Carfilzomib</strong>, and <strong>Dexamethasone </strong>(480Kd) Versus Carfilzomib and&nbsp;<br>Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)&nbsp;</p></td><td rowspan="1" colspan="1"><p>Relapse or refractory MM&nbsp;</p></td><td rowspan="1" colspan="1"><p>Participant has received at least 1 prior line of anti-myeloma therapy.&nbsp;<br>a) Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody.&nbsp;<br>B) Must not have had carfilzomib&nbsp;</p></td><td rowspan="1" colspan="1"><p>BMS&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>NCIS Chng WJ&nbsp;</strong>&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>NCIS: </strong>&nbsp;<br><strong>SGH:</strong>&nbsp;<br><strong>TTSH:&nbsp;</strong>&nbsp;</p></td></tr><tr><td rowspan="1" colspan="1"><p>R5458-ONC-2245 - An Open Label, Randomized, Phase 3 Study of <strong>Linvoseltamab</strong> (REGN5458; ANTI-BCMA X ANTICD3 Bispecific Antibody) versus the Combination of<strong>Elotuzumab</strong>, <strong>Pomalidomide </strong>and <strong>Dexamethasone</strong> (EPD), in Patients with Relapsed/Refractory Multiple Myeloma (LINKERMM3)&nbsp;</p></td><td rowspan="1" colspan="1"><p>Relapse or refractory MM&nbsp;</p></td><td rowspan="1" colspan="1"><p>Participants with MM who have received at least 1 and no more than 4 prior lines of antineoplastic MM therapies including lenalidomide and a proteasome inhibitor &nbsp;<br> Participants who have received only 1 line of prior line of antimyeloma therapy must be lenalidomide refractory (including participants with progression on or within 60 days of the last dose of lenalidomide given as maintenance).&nbsp;</p></td><td rowspan="1" colspan="1"><p>Regeneron&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>NCIS Chng WJ&nbsp;</strong>&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>NCIS: </strong>&nbsp;<br><strong>SGH:</strong>&nbsp;<br><strong>TTSH:&nbsp;</strong>&nbsp;</p></td></tr><tr><td rowspan="1" colspan="1"><p>BGB-11417-105 - A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)&nbsp;</p></td><td rowspan="1" colspan="1"><p>Relapse or refractory MM&nbsp;<br>must be t(11;14)&nbsp;</p></td><td rowspan="1" colspan="1"><p>Part 1: Participants with MM who have received =&gt; 3 including IMId, proteasome inhibitor, CD38 ab &nbsp;<br>Part 2: Participants who have received at least 1 line and less than 7 prior line of antimyeloma therapy and must be IMID and PI&nbsp;</p></td><td rowspan="1" colspan="1"><p>BeiGene Ltd.&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>NCIS Chng WJ&nbsp;</strong>&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>NCIS: </strong>&nbsp;<br><strong>SGH:</strong>&nbsp;<br><strong>TTSH:&nbsp;</strong>&nbsp;</p></td></tr><tr><td rowspan="1" colspan="1"><p>IM048-022 - A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to <strong>Lenalidomide </strong>Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)&nbsp;</p></td><td rowspan="1" colspan="1"><p>Relapse or refractory MM with either one of this:&nbsp;<br>a) renal impairment&nbsp;<br>b) no measurable disease&nbsp;<br>c) CNS involvement&nbsp;<br>d) extramedullary disease&nbsp;</p></td><td rowspan="1" colspan="1"><p>Participant has received at least 1 prior line of anti-myeloma therapy.&nbsp;<br>a) Participant must have received prior treatment with lenalidomide or PI&nbsp;<br>b) Must not have had pomalidomide and selinexor&nbsp;</p></td><td rowspan="1" colspan="1"><p>AMN&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>NCIS Chng WJ&nbsp;</strong>&nbsp;</p></td><td rowspan="1" colspan="1"><p><strong>NCIS: </strong>&nbsp;<br><strong>SGH:</strong>&nbsp;<br><strong>TTSH:&nbsp;</strong>&nbsp;</p></td></tr></tbody></table><p></p>